中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 中国科学院分子影像重点实验室
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging

文献类型：期刊论文

作者Liang, Qian1,2,3; Kong, Lingxin1,2,3; Du, Yang1,2,3; Zhu, Xu4; Tian, Jie1,2,3,5,6
刊名EXPERIMENTAL AND MOLECULAR MEDICINE
出版日期2019-07-08
卷号51页码:11
ISSN号1226-3613
DOI10.1038/s12276-019-0274-7
通讯作者Du, Yang(yang.du@ia.ac.cn) ; Zhu, Xu(drzhuxu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
英文摘要Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Sorafenib is the standard first-line treatment for advanced HCC, but its efficacy is limited. Apatinib is a small-molecule tyrosine kinas e inhibitor that has shown promising antitumor effects in gastric and non-small cell lung cancers in clinical trials, but there have been only a few studies reporting its anti-HCC effects in vitro and in HCC xenograft models. Hence, our present study systemically investigated and compared the antitumorigenic and antiangiogenic efficacy of apatinib and sorafenib in HCC in vitro and in vivo using multimodality molecular imaging, including bioluminescence imaging (BLI), bioluminescence tomography (BLT), fluorescence molecular imaging (FMI), and computed tomography angiography ( CTA). Moreover, the safety and side effects of the two drugs were systemically evaluated. We found that apatinib showed a comparable therapeutic efficacy to sorafenib for the inhibition of HCC. The drug safety evaluation revealed that both of these drugs caused hypertension and mild liver and kidney damage. Sorafenib caused diarrhea, rash, and weight loss in mice, but these effects were not observed in mice treated with apatinib. In conclusion, apatinib has similar antitumorigenic and antiangiogenic efficacy as sorafenib in HCC with less toxicity. These findings may provide preclinical evidence supporting the potential application of apatinib for the treatment of HCC patients.
WOS关键词HEPATOCELLULAR-CARCINOMA ; THERAPY ; ANGIOGENESIS ; TOMOGRAPHY ; MODELS ; TUMORS
资助项目National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022]
WOS研究方向Biochemistry & Molecular Biology ; Research & Experimental Medicine
语种英语
WOS记录号WOS:000474511300002
出版者NATURE PUBLISHING GROUP
资助机构National Key Research and Development Plan of China ; National Natural Science Foundation of China ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science and Technology Commission
源URL[http://ir.ia.ac.cn/handle/173211/26900]  
专题自动化研究所_中国科学院分子影像重点实验室
通讯作者Du, Yang; Zhu, Xu; Tian, Jie
作者单位1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing 100190, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China
4.Peking Univ, Dept Intervent Therapy, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Sch Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China
5.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med, Beijing 100191, Peoples R China
6.Xidian Univ, Engn Res Ctr Mol & Neuro Imaging, Sch Life Sci & Technol, Minist Educ, Xian 710126, Shaanxi, Peoples R China
推荐引用方式
GB/T 7714		 Liang, Qian,Kong, Lingxin,Du, Yang,et al. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging[J]. EXPERIMENTAL AND MOLECULAR MEDICINE,2019,51:11.
APA Liang, Qian,Kong, Lingxin,Du, Yang,Zhu, Xu,&Tian, Jie.(2019).Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.EXPERIMENTAL AND MOLECULAR MEDICINE,51,11.
MLA Liang, Qian,et al."Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging".EXPERIMENTAL AND MOLECULAR MEDICINE 51(2019):11.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。